Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study

N L Henry, D Pchejetski, R A'Hern, A T Nguyen, P Charles, J Waxman, L Li, A M Storniolo, D F Hayes, D A Flockhart, V Stearns, J Stebbing

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.
Original languageEnglish
Pages (from-to)291-296
Number of pages6
JournalBritish Journal of Cancer
Issue number3
Publication statusPublished - 27 Jul 2010


  • Aged
  • Androstadienes
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Bridged Compounds
  • Case-Control Studies
  • Cytokines
  • Estrogens
  • Female
  • Humans
  • Inflammation
  • Middle Aged
  • Musculoskeletal Diseases
  • Postmenopause
  • Syndrome
  • Tamoxifen
  • Taxoids

Cite this